News articles about Cumberland Pharmaceuticals (NASDAQ:CPIX) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cumberland Pharmaceuticals earned a news impact score of 0.05 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 47.0972063834011 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Separately, ValuEngine lowered shares of Cumberland Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday.

Cumberland Pharmaceuticals (NASDAQ:CPIX) opened at $7.31 on Tuesday. Cumberland Pharmaceuticals has a fifty-two week low of $5.16 and a fifty-two week high of $7.96. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.81 and a current ratio of 4.18.

TRADEMARK VIOLATION NOTICE: This report was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://theolympiareport.com/2017/12/05/cumberland-pharmaceuticals-cpix-getting-somewhat-favorable-media-coverage-analysis-finds.html.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H.

Insider Buying and Selling by Quarter for Cumberland Pharmaceuticals (NASDAQ:CPIX)

Receive News & Ratings for Cumberland Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.